Search
                    Virginia Paid Clinical Trials
A listing of 1861  clinical trials  in Virginia  actively recruiting volunteers for paid trials and research studies in various therapeutic areas.
            1549 - 1560 of 1861
        
                Virginia is currently home to 1861 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Richmond, Charlottesville, Norfolk and Fairfax. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
            
                                                Featured Trial
                
                Healthy Participants Needed (Colonoscopy + Cancer Screening)
            
        Recruiting
            
        Earn $325 - $475 in electronic payment card compensation for your time and effort by participating in a clinical study to develop a blood test that may one day help screen for colon cancer. Take a quick quiz to see if you qualify.
    
    
                            Conditions: 
                                    
        
            
                        Healthy
                    
                                    
                        Healthy Volunteers
                    
                                    
                        Healthy Subjects
                    
                                    
                        Healthy Volunteer
                    
                                    
                        Healthy Participants
                    
                                    Featured Offer
                
                Lose Weight with GLP-1 Medications
            
        Recruiting
            
        Policy Lab has partnered with OnlineSemaglutide.org to offer trusted access to semaglutide and other GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®. 
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $50 off your first program with code policy-lab-50.
    GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $50 off your first program with code policy-lab-50.
                            Conditions: 
                                    
        
            
                        Overweight
                    
                                    
                        Overweight and Obesity
                    
                                    
                        Obesity
                    
                                    
                        Weight Loss
                    
                                    
                        Morbid Obesity
                    
                                    Featured Trial
                
                Stroke Clinical Study
            
        Recruiting
            
        A clinical study for people that suffer with Stroke
    
    
                            Conditions: 
                                    
        
            
                        Stroke
                    
                                    Featured Trial
                
                Chronic Kidney Disease (CKD) Clinical Study
            
        Recruiting
            
        A clinical study for people that suffer with Chronic Kidney Disease (CKD)
    
    
                            Conditions: 
                                    
        
            
                        Chronic Kidney Disease (CKD)
                    
                                    Featured Trial
                
                Ischemic heart disease (IHD) Clinical Study
            
        Recruiting
            
        A clinical study for people that suffer with Ischemic heart disease (IHD)
    
    
                            Conditions: 
                                    
        
            
                        Ischemic heart disease (IHD)
                    
                                    
                
                                    ProSPective Evaluation of Non-contrast sINe spiN Flat-dEtectoR CT for the Detection of Intracranial hemorrhageS
                                
            
            
        Recruiting
                            
            
                Stroke is one of the leading causes of mortality and disability worldwide. Optimization of intra-hospital pathways is as of today one of the most promising research topics in stroke treatment. A potential solution to shorten the time needed for current workflows, and therefore reperfusion, is to do both imaging and subsequent endovascular therapy (EVT) in the angiography suite using non-contrast syngo DynaCT Sine Spin (FDCT) for the exclusion of intracranial hemorrhage and flat detector CT angio...  Read More             
        
        
    Gender:
                ALL
            Ages:
                18 years and above
            Trial Updated:
                01/03/2025
            
            Locations: University of Virginia Health System, Charlottesville, Virginia         
        
        
            Conditions: Stroke
        
            
        
    
                
                                    The Society for Obstetric Anesthesia and Perinatology Research Network General Anesthesia Registry
                                
            
            
        Recruiting
                            
            
                The SOAP registry is a prospective, multicenter, electronic registry. The goal is to investigate the indications, mode of airway management, predisposing factors, and obstetric and anesthetic outcomes of pregnant patients who receive general anesthesia for cesarean delivery.             
        
        
    Gender:
                FEMALE
            Ages:
                Between 15 years and 55 years
            Trial Updated:
                01/02/2025
            
            Locations: University of Virginia, Charlottesville, Virginia         
        
        
            Conditions: Cesarean Delivery, General Anesthesia
        
            
        
    
                
                                    A Study of NX-1607 in Adults With Advanced Malignancies
                                
            
            
        Recruiting
                            
            
                This is a first-in-human Phase 1a/1b multicenter, open-label oncology study designed to evaluate the safety and anti-cancer activity of NX-1607 in patients with advanced malignancies.             
        
        
    Gender:
                ALL
            Ages:
                18 years and above
            Trial Updated:
                01/02/2025
            
            Locations: University of Virginia, Charlottesville, Virginia         
        
        
            Conditions: Ovarian Cancer, Epithelial, Gastric Cancer, GastroEsophageal Junction (GEJ) Cancer, Head and Neck Squamous Cell Carcinoma, Non-small Cell Lung Cancer (NSCLC), Metastatic Castration-resistant Prostate Cancer (mCRPC), Malignant Pleural Mesothelioma (MPM), Triple Negative Breast Cancer (TNBC), Metastatic Urothelial Carcinoma, Cervical Cancer, Metastatic or Unresectable Melanoma, Diffuse Large B Cell Lymphoma (DLBCL), Richter Transformation, Microsatellite Stable Colorectal Carcinoma
        
            
        
    
                
                                    Rifaximin SSD in Dementia Trial
                                
            
            
        Recruiting
                            
            
                Using a new formulation of rifaximin, a non-absorbable antibiotic, to test if it can affect microbes in the gut of patients with dementia favorably.             
        
        
    Gender:
                ALL
            Ages:
                65 years and above
            Trial Updated:
                12/30/2024
            
            Locations: Richmond VA Medical Center, Richmond, Virginia         
        
        
            Conditions: Dementia Alzheimer Type, Dementia Associated With Cerebrovascular Disease
        
            
        
    
                
                                    Remote Ischemic Preconditioning for Renal and Cardiac Protection in Congestive Heart Failure (RICH) Trial
                                
            
            
        Recruiting
                            
            
                This is a prospective, double-blind, sham-controlled, multicenter, randomized clinical trial is to study the effects of remote ischemic preconditioning on contrast-associated acute kidney injury, functional capacity, and major adverse kidney events in in patients with congestive heart failure undergoing cardiac catheterization and/or percutaneous coronary intervention.             
        
        
    Gender:
                ALL
            Ages:
                18 years and above
            Trial Updated:
                12/27/2024
            
            Locations: Hunter Holmes McGuire VA Medical Center, Richmond, VA, Richmond, Virginia         
        
        
            Conditions: Acute Kidney Injury, Heart Failure, Contrast Induced Nephropathy, Coronary Angiography, Percutaneous Coronary Intervention
        
            
        
    
                
                                    Investigation of Metformin in Pre-Diabetes on Atherosclerotic Cardiovascular OuTcomes
                                
            
            
        Recruiting
                            
            
                This research will help us to learn if the medicine called metformin reduces the risk of death, heart attacks, and/or strokes in Veterans who have pre-diabetes and heart or blood vessel problems.             
        
        
    Gender:
                ALL
            Ages:
                18 years and above
            Trial Updated:
                12/27/2024
            
            Locations: Hunter Holmes McGuire VA Medical Center, Richmond, VA, Richmond, Virginia         
        
        
            Conditions: Prediabetic State, Atherosclerosis, Metformin
        
            
        
    
                
                                    A Phase 1/1b Study of IAM1363 in HER2 Cancers
                                
            
            
        Recruiting
                            
            
                This is a Phase 1/1b open-label, multi-center dose escalation and dose optimization study designed to evaluate the safety and preliminary efficacy of IAM1363 in participants with advanced cancers that harbor HER2 alterations.             
        
        
    Gender:
                ALL
            Ages:
                18 years and above
            Trial Updated:
                12/24/2024
            
            Locations: NEXT Oncology - Virginia Cancer Specialists, Fairfax, Virginia         
        
        
            Conditions: HER2 Mutation-Related Tumors, HER2, HER2-positive Breast Cancer, HER2 + Breast Cancer, Brain Metastases from Solid Tumors, Brain Metastases from HER2 and Breast Cancer, CNS Metastases, HER2-Positive Solid Tumors, NSCLC (non-small Cell Lung Cancer), HER2-positive Bladder Cancer, HER2-positive Colorectal Cancer, HER2 + Gastric Cancer, HER2-positive Gastroesophageal Cancer
        
            
        
    
                
                                    A Study to Investigate the Safety and Efficacy of KQB198 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies
                                
            
            
        Recruiting
                            
            
                The goal of this clinical trial is to learn if KQB198 works to treat advanced solid tumor cancer in adults. It will also learn about the safety of KQB198. The main questions it aims to answer are:
* What is the safe dose of KQB198 by itself or in combination with other anti-cancer drugs?
* Does KQB198 alone or in combination with other anti-cancer drugs decrease the size of the tumor?
* What happens to KQB198 in the body?
Participants will:
* Take KQB198 daily, alone or in combination with an...  Read More             
        
        
    Gender:
                ALL
            Ages:
                18 years and above
            Trial Updated:
                12/23/2024
            
            Locations: NEXT Oncology, Fairfax, Virginia         
        
        
            Conditions: Solid Tumor, Adult
        
            
        
    
                
                                    Testing Whether the Addition of Carboplatin Chemotherapy to Cabazitaxel Chemotherapy Will Improve Outcomes Compared to Cabazitaxel Alone in People With Castrate-Resistant Prostate Cancer That Has Spread Beyond the Prostate to Other Parts of the Body
                                
            
            
        Recruiting
                            
            
                This phase III trial compares the effect of adding carboplatin to the standard of care chemotherapy drug cabazitaxel versus cabazitaxel alone in treating prostate cancer that keeps growing even when the amount of testosterone in the body is reduced to very low levels (castrate-resistant) and that has spread from where it first started (primary site) to other places in the body (metastatic). Carboplatin is in a class of medications known as platinum-containing compounds. Carboplatin works by kill...  Read More             
        
        
    Gender:
                MALE
            Ages:
                18 years and above
            Trial Updated:
                12/20/2024
            
            Locations: VCU Massey Cancer Center at Stony Point, Richmond, Virginia         
        
        
            Conditions: Castration-Resistant Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8
        
            
        
    
                
                                    Safety and Efficacy Study of Intracystic TARA-002 for the Treatment of Lymphatic Malformations in Participants 6 Months to Less Than 18 Years of Age
                                
            
            
        Recruiting
                            
            
                This is a Phase 2a/b single arm open label study to evaluate the safety, reactogenicity, and efficacy of intracystic injection of TARA-002 in participants 6 months to less than 18 years of age for the treatment of macrocystic and mixed cystic lymphatic malformations. The Phase 2a safety lead-in, age de-escalation study is designed to establish the safety of TARA-002 in older participants 6 years to less than 18 years before proceeding to younger participants 2 years to less than 6 years, then 6...  Read More             
        
        
    Gender:
                ALL
            Ages:
                Between 6 months and 18 years
            Trial Updated:
                12/20/2024
            
            Locations: Children's Hospital of the King's Daughters, Norfolk, Virginia         
        
        
            Conditions: Lymphatic Malformation
        
            
        
    
                
                                    Study of Navtemadlin Add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients with Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib
                                
            
            
        Recruiting
                            
            
                This clinical trial is evaluating whether addition of navtemadlin to ruxolitinib treatment will provide more clinical benefit than ruxolitinib alone for patients with Myelofibrosis who have a suboptimal response to ruxolitinib treatment alone.
Subjects will start by receiving ruxolitinib alone in the run-in period. Those who demostrate a suboptimal response from ruxolitinib alone will then be randomized 2:1 to receive navtemadlin or navtemadlin placebo as add-on treatment to their ongoing ruxol...  Read More             
        
        
    Gender:
                ALL
            Ages:
                18 years and above
            Trial Updated:
                12/19/2024
            
            Locations: Virginia Cancer Institute, Richmond, Virginia         
        
        
            Conditions: Myelofibrosis, Post-PV MF, Post-ET Myelofibrosis, Primary Myelofibrosis, MF
        
            
        
    
                
                                    Effects of Hypoglossal Nerve Stimulation on Cognition and Language in Down Syndrome and Obstructive Sleep Apnea
                                
            
            
        Recruiting
                            
            
                This study is a prospective, single-arm study conducted under a common implant and follow-up protocol. The objective will be to follow fifty-seven (57) adolescents and young adults (10-21 years of age), with Down syndrome, moderate to severe sleep apnea, and post-adenotonsillectomy, for 12 months after undergoing implant of the Inspire Upper Airway Stimulation (UAS) System. The study is being conducted in order to evaluate objective change in cognition and expressive language after implant and t...  Read More             
        
        
    Gender:
                ALL
            Ages:
                Between 10 years and 21 years
            Trial Updated:
                12/19/2024
            
            Locations: Children's Hospital of the King's Daughters/East Virginia Medical School, Norfolk, Virginia         
        
        
            Conditions: Down Syndrome, Obstructive Sleep Apnea
        
            
        
    